Novo’s oral amycretin could lead to more weight loss beyond 12 weeks, according to early-stage trial

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

How AI and Intelligent Automation Can Support and Retain Nurses

Teri Ridge, RN, Clinical Operations Advisor, LeanTaaS Frontline nurses across the country remain in a state of constant crisis as they attempt to deliver patient

December 12, 2023

Apogee and Sagimet’s IPO plans come into view, with targeted raises of $228M and $66M

Apogee Therapeutics and Sagimet Biosciences offered new details on their IPO plans Monday morning, saying they look to raise $228 million and $66 million in

July 11, 2023

Another Paragon offshoot inks reverse merger as Jade takes Aerovate’s place

Paragon Therapeutics, a company that spins out antibody biotechs, has forged a second reverse merger for its portfolio this week. Its autoimmune spinoff Jade Biosciences

November 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.